193 related articles for article (PubMed ID: 36872337)
1. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
Zhang L; Wang W; Ge S; Li H; Bai M; Duan J; Yang Y; Ning T; Liu R; Wang X; Ji Z; Wang F; Zhang H; Ba Y; Deng T
BMC Cancer; 2023 Mar; 23(1):211. PubMed ID: 36872337
[TBL] [Abstract][Full Text] [Related]
2. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Cohort Study Examining the Effects of Anti-PD-1 Antibody in Combination with Apatinib in Patients Previously Treated for Her2-Negative Advanced Gastric/Gastroesophageal Junction Cancer.
Hou XF; Zhang XX; Li S; Wu C; Chen XB
J Clin Pharmacol; 2023 Jul; 63(7):769-775. PubMed ID: 37005358
[TBL] [Abstract][Full Text] [Related]
6. Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Bai Z; Zhang J; Jiang H; Yang X; Yan S; Yin J; Cai J; Zhang Z; Deng W
J Gastrointest Oncol; 2021 Oct; 12(5):2035-2044. PubMed ID: 34790371
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H; Yu X; Li N; Kong M; Ma Z; Zhou D; Wang W; Wang H; Wang H; He K; Li Z; Lu Y; Zhang J; Zhao K; Zhang Y; Xu N; Li Z; Liu Y; Wang Y; Wang Y; Teng L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296556
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
Tang Z; Wang Y; Yu Y; Cui Y; Liang L; Xu C; Shen Z; Shen K; Wang X; Liu T; Sun Y
BMC Med; 2022 Apr; 20(1):107. PubMed ID: 35382819
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer.
Wang J; He Y; Zhang B; Lv H; Nie C; Chen B; Xu W; Zhao J; Cheng X; Li Q; Tu S; Chen X
Front Oncol; 2022; 12():924149. PubMed ID: 35719979
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
13. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
Wei Q; Xu X; Li J; Wang C; Chen W; Xie Y; Luo C; Chen L; Chu J; Wu W; Han Z; Yang Y; Hu Z; Xu Q; Ying J
Oncologist; 2024 Apr; 29(4):364-e578. PubMed ID: 38366886
[TBL] [Abstract][Full Text] [Related]
14. HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y; Li N; Li Q; Liang X; Zhang S; Fan Q; Yin X; Zhuang Z; Liu Y; Zhang J; Kou X; Zhong H; Wang X; Dou Y; Huang J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060149
[TBL] [Abstract][Full Text] [Related]
15. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
16. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
19. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Zhao Y; Zhou J; Chen H; Wang M; Li L; Yang J; Liu F; Zheng L; Yin H; Yang Y; Zhou C; Zeng P; Zhou X; Ding N; Chen S; Zhao X; Yan J; Fan X; Guan W; Liu B
Nat Commun; 2023 Aug; 14(1):4904. PubMed ID: 37580320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
